Skip to main content
  • Offering
    • Offering
    • Integrated Biologics
      • Integrated Biologics
      • Expression Technologies
        • Expression Technologies
        • GS Xceed® Gene Expression System
        • GS piggyBac® Transposon Technology
        • GS Effex® Cell Line
        • GS Discovery® Transient Expression
        • bYlok® Bispecific Pairing Technology
        • XS Technologies® Platform
        • Technical Support
      • Early Derisking and Optimization
        • Early Derisking and Optimization
        • Developability Assessment
        • Manufacturability Assessment
        • Immunogenicity / Immunotoxicity Assessment
        • ​​Early Protein Expression​​​ Services​​
      • Integrated DNA-to-IND Programs
        • Integrated DNA-to-IND Programs
        • mAbs DNA-to-IND Program
        • Bispecifics DNA-to-IND Program
        • Fabs and Fc-Fusion Proteins DNA-to-IND Programs
        • Scaffolds and other Recombinant Proteins
      • Manufacturing
        • Manufacturing
        • Mammalian Drug Substance Manufacturing
        • Drug Product Manufacture
      • Mammalian Biopharmaceutical Services
        • Mammalian Biopharmaceutical Services
        • Cell Line Development
        • Tailored License Application Program
        • Process Development
        • Analytical Development
      • Parenteral Drug Product Services
        • Parenteral Drug Product Services
        • Clinical Technology Transfers
        • Biologics Formulatability
        • Product Formulation Development
        • Analytics
        • Process Development
        • Biologics Special Services
        • Large-scale Manufacturing Expansion
      • Biologics Regulatory Affairs Services
      • Knowledge Center
    • Advanced Synthesis
      • Advanced Synthesis
      • Small Molecules
        • Small Molecules
        • Drug Substance/API Services
          • Drug Substance/API Services
          • Accelerate Early Drug Development with Lonza Design2Optimize®
          • Early Phase Small Molecule Development Services
          • API Support for Early Phase Development
          • AI-Enabled Route Scouting Service
          • Solid Form Drug Services
          • PBPK Modeling Services
          • High-Throughput Experimentation (HTE) | Accelerate Chemical Optimization with Lonza
          • Pharmaceutical Method Development
          • Commercial API Manufacturing Services
          • Highly Potent API Technologies
            • Highly Potent API Technologies
            • HPAPI Handling and Development
            • HPAPI Manufacturing | Low & High Potency
          • ADC Clinical and Commercial Manufacturing
          • ADC Payload Product Development
        • Particle Engineering
          • Particle Engineering
          • Solid Dispersion Technology
          • Bioavailability Enhancement
          • Spray-Dried Dispersion Technology
        • Drug Product
          • Drug Product
          • Clinical Trial Material Manufacture, Supply
          • Formulation and Development
          • Design and Preformulation Development
          • Drug Development Workflow & Pharmaceutical Process Optimization
          • Inhalation Formulation Development
          • Integrated Offerings
        • Regulatory Affairs CMC Services
          • Regulatory Affairs CMC Services
          • CMC Development Services | CMC Regulatory Submissions
      • Bioconjugation Services
        • Bioconjugation Services
        • Early Development Bioconjugate Services | ADCs
        • ADC Drug Substance Manufacturing
        • Pharmaceutical, ADC Analytical Services
        • Targeting Agent and Carrier Protein
        • ADC Process Development
        • Ibex® Design ADC, DNA-to-IND Program
      • ADC Technologies Platform
      • Knowledge Center
    • Specialized Modalities
      • Specialized Modalities
      • Cell & Gene
        • Cell & Gene
        • Process Development
        • cGMP Manufacturing
        • Allogeneic
        • Autologous
        • Viral Vectors
        • Exosomes
      • Microbial
        • Microbial
        • Microbial Strain Development
        • Process Development
        • Drug Substance Manufacturing
        • Analytical Development
      • mRNA/LNP
        • mRNA/LNP
        • Process Development
        • Analytical Services
        • mRNA Manufacturing
        • Lipid Nanoparticles Encapsulation
      • Bioscience Products
      • Knowledge Center
    • Knowledge Center
  • Company
    • Company
    • About Us
      • About Us
      • Our One Lonza Strategy
      • Our Leadership
        • Our Leadership
        • Executive Committee
        • Board of Directors
        • Board Committees
      • Our History
      • Our Locations
    • News and Media
      • News and Media
      • News Releases
      • Images and Videos
      • Logo Guidelines
      • Blog
      • A View On - Lonza Podcast
      • Journalist Inquiries
    • Investor Relations
      • Investor Relations
      • Shareholder and Bondholder Information
        • Shareholder and Bondholder Information
        • Consensus and Analysts
        • Bond Investors and Credit Information
        • Investor FAQ
        • Share Buyback
      • Agenda and Events
      • Reporting and Presentations
      • Corporate Governance
      • Ethics and Compliance
      • Investor Inquiries and Feedback
    • Sustainability
      • Sustainability
      • Environment
      • People and Society
      • Compliance and Integrity
      • Responsible Sourcing
      • Global Quality
  • Careers
    • Careers
    • Welcome to Lonza
    • Life at Lonza
    • Employee Benefits
    • Early Career Opportunities
    • Inclusion, Diversity and Belonging
    • Join Our Talent Community
  • Contact Search
  • Cancel
  • Home
  • Advanced Synthesis
  • Bioconjugation Services
  • Ibex® Design ADC, DNA-to-IND Program

Ibex® Design ADC, DNA-to-IND Program

Bring your Antibody-Drug Conjugate vision to life and embark on a seamless journey from bench to clinic with Ibex® Design ADC.

Relying on Lonza's established expertise, this integrated program spans from Mammalian expression through Bioconjugation up to Drug Product development and manufacturing.

Talk to our experts
Monoclonal Antibody vial hand_without text_page 2&6
15 months* from DNA to IND/IMPD
8 months from DNA to tox Drug Substance​
10 months from DNA to tox Drug Product
Tailorable technical scope and timelines when necessary to meet your development needs​

Your ADC journey starts here


Ibex® Design ADC is a comprehensive program integrating speed, quality and efficiency to facilitate your CMC path to IND in just 15 months.

This unique offering provides an end-to-end supply solution with reduced complexity by combining Lonza's unparalleled mammalian & bioconjugate expertise, refined over decades, with our advanced highly potent fill & finish expertise.

Unlock the full potential of your ADC journey by harnessing the benefits of Lonza's integrated network, helping mitigate development risks for your cytotoxic bioconjugates.

* Estimated timelines. For antibodies, from DNA transfection to delivery of IND-enabling CMC modules. Subject to terms and conditions.

Shaped around you


Our standard Ibex® Design ADC timeline is streamlined through a platform approach across drug substance and drug product activities. This involves combining our pre-established analytical platform with bespoke methods designed for your specific product. The overall program timeline is defined by specific entry criteria, primarily focusing on mAb properties, chemical conjugation steps, and concentration ranges.

Additionally, Lonza can offer a higher level of flexibility on your journey to IND, by shaping our process around your molecule's profile and technical requirements. Our program scope and timeline can be tailored to your specific needs.

Our locations
Locations where this service is provided
Explore all locations
Visp, Switzerland
Basel Stücki, Switzerland
Stein, Switzerland
Explore all locations
Related Offerings
Early Development Bioconjugate Services | ADCs
Early development bioconjugation services supporting protein de-risking, scalable bioconjugates process development, and transition from preclinical...
Learn more
mAbs DNA-to-IND Program
Benefit from our fixed price, fastest DNA-to-IND program that minimizes risk and uncertainty from the start. Learn more.
Learn more
Bispecifics DNA-to-IND Program
We provide an integrated drug substance/drug product DNA to IND program with reliable timelines backed by Lonza’s 35+ years of experience in...
Learn more
ADC Process Development
Lonza's biopharmaceutical and small molecule expertise helps develop, scale-up and optimize processes for Bioconjugation manufacturing. Learn more.
Learn more
Pharmaceutical, ADC Analytical Services
Find out about Lonza's analytical capabilities for ADC manufacturing. We can support you from concept through to commercialization. Learn more.
Learn more
ADC Drug Substance Manufacturing
At Lonza we support the manufacture of various bioconjugates including high potency ADCs for clinical and commercial supply for both small scale and...
Learn more
ADC Clinical and Commercial Manufacturing
We provide access to integrated development and manufacturing services across the ADC components: antibodies, payloads, bioconjugation and sterile...
Learn more
Related Insights
Visit Knowledge Center
Webinar (on-demand)
Accelerate your ADC Journey: Filling the Need for Integrated Bioconjugate Solutions
Lonza is further reshaping the ADC landscape by introducing new Drug Product capabilities that enable end-to-end development and manufacturing of...
White paper
How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND
Speed to clinic and to market is increasingly gaining importance among biopharmaceutical drug developers. Companies ranging from small Biotech to...
Visit Knowledge Center
Latest news
View all articles
15 Jun 2026
Media Advisory
Lonza Grants Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation...
View article
9 Jun 2026
Media Advisory
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
View article
4 Jun 2026
Media Advisory
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC...
View article
7 May 2026
Media Advisory
Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology from Lonza
View article
31 Mar 2026
Media Advisory
Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into...
View article
19 Feb 2026
Media Advisory
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
View article
7 Jul 2025
Media Advisory
Lonza Launches Next Generation 4D-Nucleofector® LV Unit PRO for Improved Electroporation in GMP...
View article
22 May 2025
Media Advisory
Lonza Launches Design2Optimize® Platform to Streamline API Development
View article
View all articles
Who we are
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
Quick Links
  • Reporting Center
  • Upcoming Events
  • Knowledge Center
  • Meet The Experts
  • Our Locations
  • California CCPA Notice
  • Transparency in Coverage
Get in touch
  • Contact Us
  • Regulatory Support
© 2026 Lonza. All rights reserved.
Cookie Settings | Terms and Conditions | Legal Disclaimer | Privacy Policy | Accessibility | Sitemap